Samsung Biologics Co. is acquiring Switzerland-based PolyPeptide Group AG in an all-cash deal valued at approximately 1.46 billion Swiss francs [1].
The acquisition allows the South Korean company to scale its production capabilities and secure a stronger foothold in the competitive global contract drug-manufacturing market [1], [2].
The transaction is valued at roughly 2.7 trillion won [3]. In U.S. dollars, the deal is estimated between $1.8 billion [1] and $1.81 billion [2].
Based in South Korea, Samsung Biologics intends to use the purchase to broaden its reach in the development and production of peptides, a critical component in many modern pharmaceutical treatments [1], [2]. PolyPeptide Group, headquartered in Switzerland, specializes in the development and manufacture of peptide-based active pharmaceutical ingredients.
By integrating the Swiss firm's infrastructure, Samsung Biologics can increase its capacity to handle diverse client needs across different geographic regions. This strategic move follows a trend of consolidation within the contract development and manufacturing organization sector as firms race to meet the rising demand for complex biologics [1].
The announcement of the deal occurred between July 19 and July 20 [1], [2], [3]. The all-cash nature of the bid ensures a direct transfer of ownership, streamlining the integration of PolyPeptide Group into the Samsung Biologics corporate structure [2].
“Samsung Biologics is acquiring Switzerland-based PolyPeptide Group AG in an all-cash deal”
This acquisition signals Samsung Biologics' intent to pivot from a purely capacity-driven growth model to one that incorporates specialized chemical synthesis. By acquiring a Swiss specialist in peptides, the company reduces its reliance on external suppliers and gains a strategic operational hub in Europe, diversifying its geographical risk and expanding its technical portfolio beyond standard biologics.
